CGH
BPMC

Crossmark Global Holdings’s Blueprint Medicines BPMC Stock Holding History

Crossmark Global Holdings’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,533
Closed -$381K – 1287
2024
Q2 		$381K Buy
+3,533
New +$354K 0.01% 942

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Crossmark Global Holdings's BPMC Position: Q3 2024 in Review

Crossmark Global Holdings sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 3,533 shares — an estimated $381K sold.

Crossmark Global Holdings first reported a position in BPMC in Q2 2024 and held it in 1 quarter. The position peaked at $381K in Q2 2024. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Crossmark Global Holdings reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • Crossmark Global Holdings sold 3,533 Blueprint Medicines shares in Q3 2024, an estimated $381K.
  • Crossmark Global Holdings first reported a position in Blueprint Medicines in Q2 2024 and held it in 1 quarter.
  • Crossmark Global Holdings's Blueprint Medicines position peaked at $381K in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Crossmark Global Holdings's 13F filing for Q3 2024, filed 4 Nov 2024.